108 related articles for article (PubMed ID: 3393296)
1. Evidence that the substantia nigra is a site of action for L-DOPA.
Robertson GS; Robertson HA
Neurosci Lett; 1988 Jun; 89(2):204-8. PubMed ID: 3393296
[TBL] [Abstract][Full Text] [Related]
2. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
Robertson GS; Robertson HA
J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
[TBL] [Abstract][Full Text] [Related]
3. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.
Sarre S; Herregodts P; Deleu D; Devrieze A; De Klippel N; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):277-85. PubMed ID: 1407014
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat.
Orosz D; Bennett JP
Exp Neurol; 1992 Mar; 115(3):388-93. PubMed ID: 1537396
[TBL] [Abstract][Full Text] [Related]
6. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
Melamed E; Hefti F; Bitton V; Globus M
Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328
[TBL] [Abstract][Full Text] [Related]
7. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
Xu K; Dluzen DE
J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
[TBL] [Abstract][Full Text] [Related]
10. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
12. The site of dopamine formation in rat striatum after L-dopa administration.
Hefti F; Melamed E; Wurtman RJ
J Pharmacol Exp Ther; 1981 Apr; 217(1):189-97. PubMed ID: 7205652
[TBL] [Abstract][Full Text] [Related]
13. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
Spencer SE; Wooten GF
Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390
[TBL] [Abstract][Full Text] [Related]
14. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
16. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
17. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
Sivam SP
Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560
[TBL] [Abstract][Full Text] [Related]
18. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
19. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
Taylor MD; De Ceballos ML; Rose S; Jenner P; Marsden CD
Eur J Pharmacol; 1992 Aug; 219(2):183-92. PubMed ID: 1385171
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]